老年复杂核型急性淋巴细胞白血病病例学习
Case Study of Complex Karyotype Acute Lymphoblastic Leukemia in the Elderly
DOI: 10.12677/ACM.2022.1281042, PDF,   
作者: 张 蕊:济宁医学院临床医学院,山东 济宁;刘金彦*:济宁市第一人民医院肾内科,山东 济宁;辛春雷:济宁市第一人民医院血液内科,山东 济宁
关键词: 急性淋巴细胞白血病费城染色体特殊染色体核型Acute Lymphoblastic Leukemia Philadelphia Chromosome Special Chromosome Karyotype
摘要: 急性淋巴细胞白血病(Acute Lymphoblastic Leukemia, ALL)是一种起源于淋巴细胞的B系或T系细胞在骨髓内异常增生的恶性肿瘤性疾病。其致癌蛋白BCR/ABL有两种亚型,BCR/ABLP210和BCR/ABLP190,前者是慢性髓系白血病的标志,而后者存在于大多数费城染色体阳性(Philadelphia chromosome+, ph+)的急性淋巴细胞白血病(Ph+-ALL)患者中。Ph+-ALL是成人常见类型,约占成人ALL的25%~30%,而ph染色体阳性且BCR/ABLP190阳性的染色体核型约占15%~18%,临床特点包括年龄偏大、肝脾肿大、淋巴结肿大、高白细胞等,常累及中枢神经系统,主要表现为贫血、感染、出血、异常器官组织浸润(引发头痛、关节痛、腹痛、胸骨后压痛等)等,临床上以贫血、出血、胸骨后疼痛为首发者多见,以腹痛为首发较少见,本文将我科收治的以腹痛为首发表现的Ph+急性白血病一例报道如下。
Abstract: Acute lymphoblastic leukemia is a malignant neoplastic disorder in which B- or T-lineage cells originating from lymphocytes are dysplastic within the bone marrow. There are two subtypes of carcinogenic protein BCR/ABL, BCR/ABL P210 and BCR/ABL P190; the former is a marker of chronic myeloid leukemia, while the latter is found in most Philadelphia chromosome positive acute lymphoblastic leukemia patients. Ph+-ALL is a common type in adults, accounting for about 25%~30% of ALL adults. However, the karyotype of ph chromosome positive and BCR/ABLP190 positive chromosome is rare, accounting for about 15%~18%. Clinical features include older age, hepatosplenomegaly, enlarged lymph nodes, high white blood cells and so on, involving central nervous system. The main manifestations are anemia, infection, bleeding, abnormal organ and tis-sue infiltration (causing headache, joint pain, abdominal pain, retrosternal tenderness, etc.). It is rare to start with abdominal pain. A case of Ph+ acute leukemia with abdominal pain as the first manifestation in our department is reported as follows.
文章引用:张蕊, 刘金彦, 辛春雷. 老年复杂核型急性淋巴细胞白血病病例学习[J]. 临床医学进展, 2022, 12(8): 7221-7226. https://doi.org/10.12677/ACM.2022.1281042

参考文献

[1] Abou, D.I., Jabbour, E., Short, N.J. and Ravandi, F. (2019) Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Current Treatment Options in Oncology, 20, Article No. 4. [Google Scholar] [CrossRef] [PubMed]
[2] Terwilliger, T. and Abdul-Hay, M. (2017) Acute Lymphoblastic Leukemia: A Comprehensive Review and 2017 Update. Blood Cancer Journal, 7, e577. [Google Scholar] [CrossRef] [PubMed]
[3] 郑智康, 黄健. 1例BCR/ABL P230阳性的慢性粒细胞白血病特殊骨髓形态报道[J]. 检验医学与临床, 2021, 18(23): 3500-3503.
[4] Mesa, R.A., Jamieson, C., Bhatia, R., Deininger, M.W., Fletcher, C.D., Gerds, A.T., et al. (2017) NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. Journal of the National Comprehensive Cancer Network, 15, 1193-1207. [Google Scholar] [CrossRef] [PubMed]
[5] Martinelli, G., Boissel, N., Chevallier, P., Ottmann, O., Gökbuget, N., Topp, M.S., et al. (2017) Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment with Blina-tumomab: Results From a Phase II, Single-Arm, Multicenter Study. Journal of Clinical Oncology, 35, 1795-1802. [Google Scholar] [CrossRef
[6] Stock, W., Martinelli, G., Stelljes, M., DeAngelo, D.J., Gökbuget, N., Advani, A.S., et al. (2021) Efficacy of Inotuzumab Ozogamicin in Patients with Philadelphia Chromosome-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia. Cancer, 127, 905-913. [Google Scholar] [CrossRef] [PubMed]
[7] 赵美芳, 谭业辉. 成年人费城染色体阳性急性淋巴细胞白血病治疗现状及展望[J]. 白血病•淋巴瘤, 2020, 29(8): 509-512.
[8] Couturier, M.A., Thomas, X., Raffoux, E., Huguet, F., Berthon, C., Simand, C., et al. (2021) Blinatumomab + Ponatinib for Relapsed/Refractory Philadelphia Chromo-some-Positive Acute Lymphoblastic Leukemia in Adults. Leukemia & Lymphoma, 62, 620-629. [Google Scholar] [CrossRef] [PubMed]
[9] Shen, S., Chen, X., Cai, J., Yu, J., Gao, J., Hu, S., et al. (2020) Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lympho-blastic Leukemia: A Randomized Clinical Trial. JAMA Oncology, 6, 358-366. [Google Scholar] [CrossRef] [PubMed]
[10] Rafei, H., Kantarjian, H.M. and Jabbour, E.J. (2019) Recent Advances in the Treatment of Acute Lymphoblastic Leukemia. Leukemia & Lymphoma, 60, 2606-2621. [Google Scholar] [CrossRef] [PubMed]
[11] Zhang, Y., Gao, Y., Zhang, H., Zhang, J., He, F., Hnízda, A., et al. (2018) PDGFRB Mutation and Tyrosine Kinase Inhibitor Resistance in Ph-Like Acute Lymphoblastic Leuke-mia. Blood, 131, 2256-2261. [Google Scholar] [CrossRef] [PubMed]
[12] Sun, Y.Q., Li, S.Q., Zhao, X.S. and Chang, Y.J. (2020) Measurable Residual Disease of Acute Lymphoblastic Leukemia in Allograft Settings: How to Evaluate and Intervene. Expert Review of Anticancer Therapy, 20, 453-464. [Google Scholar] [CrossRef] [PubMed]
[13] Li, J., Dai, Y., Wu, L., Zhang, M., Ouyang, W., Huang, J., et al. (2021) Emerging Molecular Subtypes and Therapeutic Targets in B-Cell Precursor Acute Lymphoblastic Leukemia. Frontiers of Medicine, 15, 347-371. [Google Scholar] [CrossRef] [PubMed]
[14] Rabin, K.R. (2020) Optimizing Targeted Therapy for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. JAMA Oncology, 6, 333-334. [Google Scholar] [CrossRef] [PubMed]
[15] Warraich, Z., Tenneti, P., Thai, T., Hubben, A., Amin, H., McBride, A., et al. (2020) Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Phil-adelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review. Biology of Blood and Marrow Transplantation, 26, e55-e64. [Google Scholar] [CrossRef] [PubMed]